{"product_id":"prct-vrio-analysis","title":"PROCEPT BioRobotics Corporation (PRCT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs PROCEPT BioRobotics Corporation (PRCT) truly built for lasting success? This VRIO analysis cuts straight to the heart of their competitive advantage, scrutinizing whether their assets are Valuable, Rare, Inimitable, and Organized for superior performance. Uncover the distilled summary of their strategic strengths and weaknesses right here, and see exactly what keeps them ahead of the curve - or where they might be exposed - by reading on below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePROCEPT BioRobotics Corporation (PRCT) - VRIO Analysis: The HYDROS Robotic System and Aquablation IP\n\u003c\/h2\u003e\n\n\u003cp\u003eYou are looking at the core engine driving PROCEPT BioRobotics Corporation’s momentum. The HYDROS Robotic System and its proprietary Aquablation Intellectual Property (IP) are the clear source of their current competitive edge, which the numbers from late 2025 strongly support.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: The AI-Powered Difference\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe HYDROS Robotic System is the only AI-powered technology delivering Aquablation therapy, making treatment effective for Benign Prostatic Hyperplasia (BPH) regardless of prostate size or surgeon skill. This capability translates directly into market traction; for instance, U.S. handpiece and consumables revenue hit \u003cstrong\u003e$44.4 million\u003c\/strong\u003e in Q3 2025, marking a \u003cstrong\u003e50%\u003c\/strong\u003e year-over-year increase. That’s real value creation right there.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: A Unique Combination\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe rarity stems from the specific blend of real-time ultrasound guidance, robotics, and heat-free waterjet ablation. No one else combines these elements in a single platform today. Furthermore, the therapy’s clinical acceptance is solidifying its uniqueness, evidenced by the assignment of a Category I Current Procedural Terminology (CPT) code set to take effect on January 1, 2026, replacing the older Category III code.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Patent Moat and Software Depth\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCopying this is tough. The difficulty lies in replicating the core patents surrounding the waterjet delivery and, critically, the embedded software and AI that guides the procedure. Building that level of integrated, validated clinical software takes years and significant capital, creating a high barrier to entry for competitors.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Strong Commercial Execution\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization is structured to capitalize on this asset. The technology is the direct engine behind the firm’s growth; the \u003cstrong\u003e50%\u003c\/strong\u003e jump in U.S. handpiece revenue in Q3 2025 is a direct result of commercial execution against this unique offering. As of September 30, 2025, the U.S. installed base stood at \u003cstrong\u003e653\u003c\/strong\u003e robotic systems, up by \u003cstrong\u003e58\u003c\/strong\u003e units in that single quarter, showing the sales and service structure is effectively deploying the asset.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained Potential\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhen you combine a valuable, rare, and hard-to-copy asset with an organization that is clearly driving revenue from it - like the \u003cstrong\u003e43%\u003c\/strong\u003e total revenue growth to \u003cstrong\u003e$83.3 million\u003c\/strong\u003e in Q3 2025 - you have the makings of a sustained advantage. The company is using this IP to drive its full-year 2025 revenue guidance toward \u003cstrong\u003e$325.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick look at the Q3 2025 operational metrics supporting this advantage:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S. Handpiece Revenue: \u003cstrong\u003e$44.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal Revenue Growth (YoY): \u003cstrong\u003e43%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNew U.S. Systems Placed (Q3 2025): \u003cstrong\u003e58\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal U.S. Installed Base (Sept 30, 2025): \u003cstrong\u003e653\u003c\/strong\u003e systems\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTo be fair, utilization growth in Q3 was only in the low single digits, which management noted, but they are launching initiatives to fix that. Still, the underlying asset strength is undeniable.\u003c\/p\u003e\n\u003cp\u003eFinance: Review the Q4 2025 operating expense forecast against the new CEO’s stated focus on patient activation initiatives by next Tuesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePROCEPT BioRobotics Corporation (PRCT) - VRIO Analysis: Recurring Consumables Revenue Stream\n\u003c\/h2\u003e\n\u003cp\u003e\nThe recurring consumables revenue stream, driven by the use of disposable handpieces with the installed base of HYDROS® Robotic Systems, is a critical component of the PRCT financial structure.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHandpieces and consumables generate high-margin, predictable revenue streams that support ongoing operations and Research \u0026amp; Development investments. The Gross Margin for the third quarter of 2025 was reported at 64.8%.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nWhile other device companies utilize a razor-and-blade model, the rate of growth in this segment for PRCT is exceptional. U.S. handpiece and consumable revenue for the third quarter of 2025 reached $44.4 million, representing a year-over-year increase of 50%.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nCompetitors face the hurdle of system placement and subsequent capture of recurring usage. As of September 30, 2025, the U.S. installed base of robotic systems stood at 653 systems. The company added 58 new robotic systems in the U.S. during the third quarter of 2025. Full-year 2025 guidance included expected handpiece sales of approximately 52,000 units.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nOrganizational effectiveness is evidenced by the financial results derived from this stream. The company reported $44.4 million in U.S. handpiece and consumable revenue for the third quarter of 2025.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eTemporary\u003c\/strong\u003e\n\u003c\/p\u003e\n\n\u003cp\u003e\nSupporting metrics for the consumables stream include:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 U.S. Handpiece and Consumable Revenue: \u003cstrong\u003e$44.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Year-over-Year Growth for U.S. Handpiece\/Consumables: \u003cstrong\u003e50%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Handpieces Sold (Units): Approximately \u003cstrong\u003e13,225\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEstimated Handpiece Average Selling Price (ASP) for Full Year 2025: Approximately \u003cstrong\u003e$3,200\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\nThe following table summarizes key figures related to system placement and consumable generation:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Date\u003c\/th\u003e\n\u003cth\u003eCitation Source\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Handpiece \u0026amp; Consumable Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$44.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Handpiece \u0026amp; Consumable Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Robotic System Installed Base\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e653 systems\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew U.S. Robotic Systems Placed\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e58 systems\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e64.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003ePROCEPT BioRobotics Corporation (PRCT) - VRIO Analysis: Extensive Clinical Validation Base\n\u003c\/h2\u003e\n\u003cp\u003eThe clinical validation base for Aquablation therapy is a cornerstone of PROCEPT BioRobotics' competitive positioning.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Over \u003cstrong\u003e150\u003c\/strong\u003e peer-reviewed publications build deep credibility and reduce surgeon adoption friction. BPH impacts approximately \u003cstrong\u003e40 million\u003c\/strong\u003e men in the United States.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; a large, established body of evidence is a massive moat in medical devices. Aquablation therapy is the only BPH technology randomized against TURP, the historical standard of care for surgical intervention.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very difficult; this takes years of successful trials and peer review to build. The clinical evidence includes \u003cstrong\u003enine\u003c\/strong\u003e clinical studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good; the clinical team effectively supports the commercial message. The company reported total revenue of \u003cstrong\u003e$79.2 million\u003c\/strong\u003e for the second quarter of 2025, an increase of \u003cstrong\u003e48%\u003c\/strong\u003e compared to the prior year period.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeer-Reviewed Publications\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e150\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSupporting Aquablation therapy benefits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Robotic System Install Base\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e595\u003c\/strong\u003e systems\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$79.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-year growth of \u003cstrong\u003e48%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 U.S. Consumables Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-year growth of \u003cstrong\u003e58%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiscal Year 2025 Revenue Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$325.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRepresents \u003cstrong\u003e45%\u003c\/strong\u003e growth over 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFurther supporting data points include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eU.S. handpiece and consumable revenue for the second quarter of 2025 was \u003cstrong\u003e$43.1 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e58%\u003c\/strong\u003e compared to the prior year period.\u003c\/li\u003e\n\u003cli\u003eGross margin for the second quarter of 2025 was \u003cstrong\u003e65%\u003c\/strong\u003e compared to \u003cstrong\u003e59%\u003c\/strong\u003e in the prior year period.\u003c\/li\u003e\n\u003cli\u003eFiscal year 2026 total revenue guidance is in the range of \u003cstrong\u003e$410 to $430 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIn the second quarter of 2025, the company sold \u003cstrong\u003e51\u003c\/strong\u003e robotic systems in the U.S.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePROCEPT BioRobotics Corporation (PRCT) - VRIO Analysis: Growing Installed Base of Systems\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The installed base of \u003cstrong\u003e653 U.S. systems\u003c\/strong\u003e as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e is the platform for future recurring revenue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; systems can be purchased, but the rate of placement is what matters.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; it requires capital investment and sales execution to match.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; they added \u003cstrong\u003e58 new robotic systems\u003c\/strong\u003e in the third quarter of \u003cstrong\u003e2025\u003c\/strong\u003e alone.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary\u003c\/p\u003e\n\n\u003cp\u003eThe growing installed base supports significant revenue streams:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eU.S. system and rental revenue for the third quarter of \u003cstrong\u003e2025\u003c\/strong\u003e was \u003cstrong\u003e$24.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eU.S. handpiece and consumable revenue for the third quarter of \u003cstrong\u003e2025\u003c\/strong\u003e was \u003cstrong\u003e$44.4 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e50%\u003c\/strong\u003e compared to the prior year period.\u003c\/li\u003e\n\u003cli\u003eTotal revenue for the third quarter of \u003cstrong\u003e2025\u003c\/strong\u003e was \u003cstrong\u003e$83.3 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e43%\u003c\/strong\u003e compared to the prior year period.\u003c\/li\u003e\n\u003cli\u003eThe average selling price for systems in the third quarter of \u003cstrong\u003e2025\u003c\/strong\u003e was approximately \u003cstrong\u003e$435,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFiscal year \u003cstrong\u003e2025\u003c\/strong\u003e total revenue guidance is maintained at approximately \u003cstrong\u003e$325.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFiscal year \u003cstrong\u003e2026\u003c\/strong\u003e total revenue guidance is in the range of \u003cstrong\u003e$410 to $430 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Q3 2025 or As of Sept 30, 2025)\u003c\/th\u003e\n\u003cth\u003eComparison\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Installed Base\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e653 systems\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Systems Added (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e58 systems\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease in U.S. installed base during the quarter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. System Revenue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e26%\u003c\/strong\u003e compared to prior year period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Handpiece\/Consumable Revenue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$44.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e50%\u003c\/strong\u003e compared to prior year period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$83.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e43%\u003c\/strong\u003e compared to prior year period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e65%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to \u003cstrong\u003e63%\u003c\/strong\u003e in the prior year period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003ePROCEPT BioRobotics Corporation (PRCT) - VRIO Analysis: Strong Gross Margin Profile\n\u003c\/h2\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eQ3 2025 Gross Margin reached \u003cstrong\u003e65%\u003c\/strong\u003e, with a reported figure of \u003cstrong\u003e64.8%\u003c\/strong\u003e, demonstrating operational efficiency against a Q3 2025 Net Loss of \u003cstrong\u003e$21.4 million\u003c\/strong\u003e. Total Revenue for Q3 2025 was \u003cstrong\u003e$83.3 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eThe achieved margin level is notable for a scaling robotic platform company.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eRequires optimized manufacturing and supply chain control.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eEffective management is evidenced by margin expansion from lower periods. For instance, the Q2 2025 margin of \u003cstrong\u003e64%\u003c\/strong\u003e expanded from \u003cstrong\u003e59%\u003c\/strong\u003e in the prior year period (Q2 2024). Operating Expenses in Q3 2025 were \u003cstrong\u003e$77.2 million\u003c\/strong\u003e, an increase from \u003cstrong\u003e$59.3 million\u003c\/strong\u003e in the prior year period.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025 Guidance Range\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e65%\u003c\/strong\u003e (or \u003cstrong\u003e64.8%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e64.0% to 64.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$83.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$325.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e, supported by strong consumable revenue growth.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eU.S. Handpiece and Consumables Revenue for Q3 2025: \u003cstrong\u003e$44.4 million\u003c\/strong\u003e, a \u003cstrong\u003e50%\u003c\/strong\u003e increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eU.S. Handpiece Unit Sales in Q3 2025: Approximately \u003cstrong\u003e13,225\u003c\/strong\u003e units.\u003c\/li\u003e\n\u003cli\u003eFull Year 2025 Handpiece Average Selling Price guidance: Approximately \u003cstrong\u003e$3,200\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eU.S. Installed Base as of September 30, 2025: \u003cstrong\u003e653 systems\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePROCEPT BioRobotics Corporation (PRCT) - VRIO Analysis: Robust Balance Sheet Liquidity\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eThe \u003cstrong\u003e$297.3 million\u003c\/strong\u003e cash, cash equivalents and restricted cash balances as of September 30, 2025, funds aggressive growth and absorbs operating losses. The third quarter of 2025 reported a net loss of \u003cstrong\u003e$21.4 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh; a cash position of \u003cstrong\u003e$297.3 million\u003c\/strong\u003e provides a significant runway in a pre-profitability phase, evidenced by the reiterated full-year 2025 Adjusted EBITDA loss of approximately \u003cstrong\u003e($35.0) million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLow; this liquidity level was earned through successful equity financing and strong revenue growth, with full-year 2025 revenue guidance of approximately \u003cstrong\u003e$325.5 million\u003c\/strong\u003e, representing \u003cstrong\u003e45%\u003c\/strong\u003e growth over the prior year.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003ePrudent; financial management has maintained a strong liquidity position relative to outstanding obligations, such as long-term borrowings of \u003cstrong\u003e$52.0 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eSustained\u003c\/p\u003e\n\u003cp\u003eKey Financial Metrics Supporting Liquidity Assessment:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Rate\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Restricted Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$297.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-Term Borrowings\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$52.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2025 Revenue Guidance\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$325.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2025 Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e45%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther Financial Details:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eU.S. handpiece and consumable revenue for Q3 2025 increased \u003cstrong\u003e50%\u003c\/strong\u003e compared to the prior year period.\u003c\/li\u003e\n\u003cli\u003eU.S. system revenue for Q3 2025 increased \u003cstrong\u003e26%\u003c\/strong\u003e compared to the prior year period.\u003c\/li\u003e\n\u003cli\u003eThe install base of robotic systems in the U.S. was \u003cstrong\u003e653 systems\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eFull Year 2025 gross margin guidance is in the range of \u003cstrong\u003e64.0% to 64.5%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eReiterated full year 2025 total operating expense is approximately \u003cstrong\u003e$302.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePROCEPT BioRobotics Corporation (PRCT) - VRIO Analysis: Prostate Cancer Clinical Pipeline (WATER IV PCa)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e FDA-IDE approval to start the WATER IV PCa study opens a much larger indication beyond BPH. The technology also received \u003cstrong\u003eBreakthrough Device Designation\u003c\/strong\u003e from the FDA for prostate cancer treatment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; competitors are also targeting prostate cancer, but this is a concrete step forward with a pivotal trial underway.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires navigating complex regulatory pathways for pivotal trials, evidenced by the recent FDA-IDE approval.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Focused; R\u0026amp;D is clearly prioritizing this high-potential expansion. Full Year 2024 Operating Expenses were \u003cstrong\u003e$233.7 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary\u003c\/p\u003e\n\u003cp\u003eThe WATER IV PCa trial is a global multicenter, prospective, randomized clinical study comparing Aquablation therapy to radical prostatectomy in men with Grade Group 1 to 3 localized prostate cancer.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe trial is designed to enroll up to \u003cstrong\u003e280 patients\u003c\/strong\u003e across up to \u003cstrong\u003e50 centers\u003c\/strong\u003e globally.\u003c\/li\u003e\n\u003cli\u003ePatients will be followed for up to \u003cstrong\u003e10 years\u003c\/strong\u003e, with a co-primary endpoint based on morbidity evaluated at the \u003cstrong\u003esix-month\u003c\/strong\u003e follow-up.\u003c\/li\u003e\n\u003cli\u003eA prior feasibility study (NCT06054867) planned to enroll approximately \u003cstrong\u003e22 adult patients\u003c\/strong\u003e across \u003cstrong\u003e3 clinical trial sites\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnalysts suggest the potential market unlocked by this indication could be valued at \u003cstrong\u003e$500 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAquablation (Reported Rates)\u003c\/td\u003e\n\u003ctd\u003eRadical Prostatectomy (Existing Data)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eErectile Dysfunction Rate (Post-Procedure)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0%\u003c\/strong\u003e to low-single-digit rates\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20%\u003c\/strong\u003e to \u003cstrong\u003e55%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUrinary Incontinence Rate (Post-Procedure)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0%\u003c\/strong\u003e to low-single-digit rates\u003c\/td\u003e\n\u003ctd\u003eAround \u003cstrong\u003e20%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company sold \u003cstrong\u003e60\u003c\/strong\u003e new robotic systems in the U.S. in the fourth quarter of 2024 at a blended average selling price of approximately \u003cstrong\u003e$460,000\u003c\/strong\u003e. Full Year 2024 Gross Margin was \u003cstrong\u003e61%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePROCEPT BioRobotics Corporation (PRCT) - VRIO Analysis: Rapid Commercial Growth Trajectory\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Projected full-year 2025 revenue of \u003cstrong\u003e$325.5 million\u003c\/strong\u003e represents \u003cstrong\u003e45%\u003c\/strong\u003e growth over the prior year, signaling strong market acceptance.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; this pace of growth is evidenced by year-over-year revenue increases such as \u003cstrong\u003e48%\u003c\/strong\u003e in Q2 2025 and \u003cstrong\u003e43%\u003c\/strong\u003e in Q3 2025 in a specialized med-tech segment.\u003c\/p\u003e\n\u003cp\u003eThe commercial momentum is detailed in the following financial performance metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Value\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Value\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025 Projection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$79.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$83.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$325.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Handpiece \u0026amp; Consumables Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$44.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot specified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. System \u0026amp; Rental Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$93.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Robotic Systems Placed (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e51\u003c\/strong\u003e systems\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e58\u003c\/strong\u003e systems added to base\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e210\u003c\/strong\u003e units guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Installed Base (End of Period)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e595\u003c\/strong\u003e systems (as of June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e653\u003c\/strong\u003e systems (595 + 58)\u003c\/td\u003e\n\u003ctd\u003eNot specified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires an effective sales force and physician training infrastructure, as evidenced by the need to expand the commercial organization and the reported sales force quota attainment challenges.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; the commercial team is clearly executing well against the plan, demonstrated by:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eU.S. system sales guidance of \u003cstrong\u003e210\u003c\/strong\u003e units for the full year 2025.\u003c\/li\u003e\n\u003cli\u003eU.S. handpiece sales forecast of approximately \u003cstrong\u003e53,000\u003c\/strong\u003e units for the full year 2025.\u003c\/li\u003e\n\u003cli\u003eTotal operating expenses projected at approximately \u003cstrong\u003e$302.0 million\u003c\/strong\u003e for full year 2025, reflecting investment in expansion.\u003c\/li\u003e\n\u003cli\u003eApproximately \u003cstrong\u003e32%\u003c\/strong\u003e of sales representatives typically meet or exceed their annual quota based on past year ratings.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePROCEPT BioRobotics Corporation (PRCT) - VRIO Analysis: New CEO with Deep MedTech Experience\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eNew CEO with Deep MedTech Experience\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: The arrival of Larry Wood in September 2025 brings \u003cstrong\u003e40 years\u003c\/strong\u003e of leadership experience to guide the next phase. Mr. Wood previously served as Corporate Vice President, Transcatheter Aortic Valve Replacement, at Edwards Lifesciences Corporation since February 2007.\u003c\/p\u003e\n\u003cp\u003eRarity: Moderate; executive talent is mobile, but specific, relevant experience is not easily found. Mr. Wood has experience at both Edwards Lifesciences Corporation and Baxter Healthcare Corporation.\u003c\/p\u003e\n\u003cp\u003eImitability: Low; you can’t just hire a specific person’s history. Mr. Wood has served as a member of the Company’s Board since April 2024.\u003c\/p\u003e\n\u003cp\u003eOrganization: Newly established but critical; his early confidence is a positive signal. The appointment was effective as of September \u003cstrong\u003e2, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Temporary\u003c\/p\u003e\n\u003cp\u003eHonestly, the sustained advantage comes from the IP and the clinical proof, but the temporary ones - like the cash pile and the new CEO - are what will fuel the next 18 months of growth. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\u003cp\u003eThe transition follows a period of significant growth under the previous CEO, Dr. Reza Zadno, who led the company through a successful 2021 public offering and saw global Aquablation procedures reach nearly \u003cstrong\u003eone hundred thousand\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key financial and operational metrics around the time of the leadership transition:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$83.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue Year-over-Year Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e43%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 vs. Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Handpiece \u0026amp; Consumables Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$44.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. System \u0026amp; Rental Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Robotic System Install Base\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e653 systems\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Restricted Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$297.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year 2025 Revenue Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$325.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReiterated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe new CEO's direct ownership and the company's recent financial performance provide context for the temporary advantage:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLarry L. Wood directly owns \u003cstrong\u003e0.004%\u003c\/strong\u003e of the company's shares, valued at \u003cstrong\u003e$85.76K\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull Year 2025 total operating expense guidance is approximately \u003cstrong\u003e$302.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Net loss for Q3 2025 was \u003cstrong\u003e$21.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA loss for Q3 2025 was \u003cstrong\u003e$7.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull Year 2025 Adjusted EBITDA loss is reiterated to be approximately \u003cstrong\u003e($35.0) million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross margin for Q3 2025 was \u003cstrong\u003e65%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516234358933,"sku":"prct-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/prct-vrio-analysis.png?v=1740207686","url":"https:\/\/dcf-model.com\/fr\/products\/prct-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}